In most countries the prevalence of kidney stones has increased over the past 50 years. In the USA the prevalence of stones in 2010 was 8.8%, compared with 5.5% in 1994 (REF. 1). Stone prevalence is higher among men than among women (10.6% versus 7.1% in the USA in 2010) and higher among white non-hispanic individuals than among black non-hispanic individuals 1 . At least 35% of first time stone formers will have one or more recurrences. As stone disease often affects adults during their working years, the costs of this disease include medical intervention as well as time lost from work, school, or family care, and exceed $10 billion yearly in the USA 2 . The majority of stones (85%) contain primarily calcium oxalate (CaOx) admixed with some calcium phosphate (CaP) in the form of apatite or brushite, or occasionally uric acid; less commonly they can be composed primarily of CaP 3 . Non-calcium stones can be made of uric acid or cystine. Although many systemic diseases, such as primary hyperparathyroidism, bowel disease and renal tubular acidosis, can result in calcium stone formation, the majority of calcium stones are found in people with no systemic illness. Many idiopathic patients who form calcium stones have metabolic abnormalities that can be detected by 24 h urine analysis but are not considered to be systemic diseases. Among the most common of these abnormalities is idiopathic hypercalciuria 4 . This disorder has been shown to be heritable, but is also influenced by environmental factors such as diet.
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Most kidney stones seen in clinical practice are idiopathic calcium stones, and the most common predisposing factor in these patients is hypercalciuria. In this Review, we focus on these patients, and discuss the mechanisms of idiopathic calcium stone formation as well as potential therapeutic strategies to correct hypercalciuria and reduce the risk of stone formation.
Patient phenotyping
A traditional method of phenotyping patients with calcium stones includes analysis of stone crystal composition as well as consideration of the presence or absence of established diseases that could cause stones. Among idiopathic patients, those whose stones are predominantly composed of CaOx (>50%) are considered to be a separate group from those whose stones are predominantly composed of CaP crystals such as apatite or brushite 5 . Modern endoscopy techniques enable direct renal papillary visualization during stone surgery and this advance has added papillary morphology to patient phenotyping. Direct biopsy of the papillum enables additional refinement of the stone phenotype but this research tool is unlikely to be used for patient care.
Formation of idiopathic calcium stones
A key question regarding calcium stone formation is whether these stones form in contact with renal tissue or in the bulk urine without a direct tissue interaction. The available evidence demonstrates that calcium stones do form in contact with tissue, but proof that formation in urine can also occur is lacking. If the predominant way in which stones form is on anchored sites in the renal papillae, then the nature of those sites, and the way in which they occur, is an important part of the story of stone pathogenesis.
Growth on interstitial apatite deposits
Clinically important CaOx stones can form as overgrowths on interstitial apatite deposits known as Randall's plaque 6 . During percutaneous or ureteroscopic stone removal surgery, CaOx stones -including stones of clinically significant size -can be seen growing on human renal papillae (FIG. 1) . These stones can be detached only with some effort, whereupon an attachment site can be seen on the stone. In some cases, the corresponding regions of attachment on the renal papillae are also visible to the surgeon.
In a study that included nine patients with idiopathic CaOx stones (those with systemic disease were excluded), we found that 78% of 115 stones visualized at surgery were attached to papillae, and of these 90% were attached over plaque, which itself occupied ≤5% of the papillary surface area 7 . In a separate study of unattached stones in the same patients, evidence of an attachment site -an apatite deposit -was present on all of these stones, suggesting an origin on plaque 8 . The percentage of patients without hypercalciuria who form CaOx stones on plaque is unknown. In an unselected population of 78 patients who underwent percutaneous nephrolithotomy (PNL), Linnes et al. identified 37 patients (of whom 26 were female) with idiopathic CaOx stones 9 . These patients were not remarkably hypercalciuric (mean 24 h urinary calcium level of 210 mg). Although the researchers reported a mean plaque surface area coverage of 3.6%, they did not indicate whether or not the CaOx stones were found on plaque. In a subsequent study that included 42 idiopathic patients with CaOx stones who underwent PNL, abundant plaque (>5% surface area coverage) was found in 10 patients (of whom six were male) 10 . These patients had higher urinary calcium excretion (291 mg per day) than those with lower plaque abundance (of whom eight were male; 187 mg per day). In a third study, these researchers found no evidence of increased plaque or urine calcium in 95 patients who formed idiopathic CaOx stones (of whom 42 were male) compared with 19 healthy individuals or 23 patients who formed uric acid stones 11 . Although these studies from a single group of investigators do not report the location in which the stones were formed, analysis of stones by micro-CT showed that those from patients with >5% plaque surface area coverage were more likely to show evidence of growth on plaque than those from patients with <5% plaque surface area coverage 11 . Future surgical series will clarify the frequency with which stone growth on plaque can be documented using endoscopy.
Formation of stones on plaque can also be investigated via careful analysis of the stones themselves. In a large series of stones analysed in a French laboratory using infrared spectroscopy and morphoconstitutional analysis, 34% of 30,149 intact stones collected between 1989 and 2013 that were at least 85% CaOx showed evidence of having formed over Randall's plaque 12 . Moreover, a marked increase in the frequency of nucleation of stones over plaque occurred between 1990 and 2010 in men and in women, particularly in young adults. Analysis of CaOx stones passed between 2009 and 2011 showed that among patients aged 20-29 years, approximately 60% of those passed by women and 50% of those passed by men had nucleated over plaque, compared with 20% of those passed by women and 25% of those passed by men aged ≥70 years. It is not possible to determine how many of these patients were idiopathic stone formers, but it is probable that the majority did not have systemic disease.
The phenomenon of CaOx stones growing on interstitial plaque has also been observed in patients with CaOx stones owing to primary hyperparathyroidism 13 , ileostomy 14 and small bowel resection 15 as well as in idiopathic patients whose stones are composed mainly of hydroxyapatite 16 or brushite 17 . Patients who form idiopathic hypercalciuric CaOx stones are unique, however, because growth on plaque seems to be the major mechanism of stone formation and plaque is often the only renal tissue mineralization. In patients with systemic diseases and in patients who form hydroxyapatite or brushite stones, growth on plaque is found in combination with a different kind of tissue mineralization: plugging of inner medullary and papillary collecting ducts with crystals of hydroxyapatite, brushite or CaOx, depending on the clinical condition 18 .
Plaque formation. The initial sites of plaque formation are the basement membranes of the thin limbs of the loops of Henle, in which plaque appears as microspherules of alternating organic and apatite crystal laminations 19 (FIG. 2) . Subsequently, either by extension or additional formation, plaque appears in the papillary interstitium. Plaque that forms in this location is an High resolution CT imaging of plaque within intraoperative tissue biopsy samples from patients with idiopathic CaOx stones supports the idea of plaque extension from the thin limbs of the loops of Henle into the interstitium. In some images mineral can be seen forming along the long axis of a thin limb and merging smoothly with the plate-like interstitial plaque 22 . An analysis of papillary biopsy samples from 12 patients with idiopathic CaOx stones who underwent PNL identified plaque in all patients 23 . The plaque deposits were located in the interstitium and in the basement membrane of the tubular epithelium; the specific tubule segments involved were not reported. X-ray dispersive microanalysis showed that the deposits were composed of calcium and phosphate. In the interstitium, plaque deposits were mixed in with long thin fibres of collagen. These fibres act as a scaffold for the heterogeneous nucleation of CaP crystal as is seen in bone formation.
The mechanisms that lead to the formation of interstitial plaque are unknown. A role of osteogenesis can be excluded because the critical bone genes RUNX2 and SP7 (also known as Osterix) were not expressed at sites of plaque in biopsy samples from nine patients with idiopathic CaOx stones 24 . By contrast, these genes were expressed in samples from 10 of 12 patients with medullary sponge kidney disease 24 . The rather primitive papillary interstitial cells of patients with medullary sponge kidney do express RUNX2 and SP7, but the sites of expression are never the sites of mineral deposition. In patients with medullary sponge kidney, tiny stones can be found within dilated cystic terminal collecting ducts, but bone genes are not expressed at these sites.
We have observed that plaque coverage is a direct function of urine calcium excretion and an inverse function of urine pH and urine volume 25 . The mechanism by which urine calcium influences plaque formation might relate to renal tubule calcium reabsorption, which is decreased in stone formers with hypercalciuria, whereas calcium delivery to the distal nephron is increased.
In the outer renal medulla, the vascular bundles are surrounded by a ring of thick ascending limb (TAL), which reabsorbs calcium independently of water 26 . Calcium reabsorption in the TAL occurs mainly via the para cellular pathway 27 and is driven by the transepithelial voltage difference between tubule lumen and the blood. As delivery of calcium to the TAL increases, reabsorption of calcium will tend to increase at the same rate, and as water is not reabsorbed the concentration of calcium within the vascular bundles will increase. The descending vasa recta provide blood to the papillary capillary network that surrounds the thin limbs of the Loop of Henle in which plaque particles originate 19 . In principle increased proximal tubule delivery of calcium can, therefore, foster papillary plaque formation via a mechanism that we have called 'vas washdown' (REF. 28 ). This idea is compatible with what is known about plaque formation and renal physiology, but has yet to be proven experimentally. Supersaturations in the papillary interstitium that might affect plaque formation are largely independent of urine supersaturation, and these two types of supersaturation have different physiological causes.
Stoller and colleagues published arguments in favour of plaque genesis in the vasa recta, based on a study of cadaveric kidneys from 50 consecutive autopsies (including those of two individuals who were stone formers) in which papillary calcifications were radiologically detected in 57% of kidneys. Calcifications were found in the interstitium around tubules, and hypertension was the factor most strongly associated with such calcifications 29 . Epidemiologic data linking stone formation to cardiovascular disease has been cited as supporting a link with vascular disease 30, 31 , however histologic evidence of a vascular site of origin is not evident in the majority of data on stone formation.
Two animal models of plaque formation have been produced: the NHERF-1 knockout mouse and a uromodulin (also known as Tamm-Horsfall protein) . These models might prove to be a promising tool for further investigations into the pathogenesis of renal stones.
Stone formation over plaque. The process of CaOx stone formation over plaque cannot proceed unless the urothelium is compromised such that urine supersaturations drive new crystal formation. The exposed surface of plaque is covered by a multilayered ribbon of alternating crystals and organic matrix, which faces the urinary space (FIG. 2) . Given that plaque is exposed to urine, the formation of an inner organic layer seems to be the first event. As this layer contains uromodulin it must be of urine origin 33 . Successive layers of hydroxyapatite nucleation and organic overlays create the multilaminar covering ribbon over the exposed plaque. The form of apatite in the ribbon is amorphous 33 ; it does not have the exact structure of mature apatite and is rather in the form of tiny highly hydrated crystals. This form transitions to mature apatite at the urinary surface, which creates larger and more angular spiky crystals that build up the apatite-matrix base of the new stone. This base can be seen when stones are removed, or when unattached stones that have formed on plaque are carefully inspected 6 . The processes that convert the orderly laminations of the ribbon into the less regular and more bulky stone base, and convert apatite nucleation into CaOx nucleation to make up the bulk of the final stone, are unknown but presumably involve conversion of amorphous apatite into mature apatite.
Growth on tubule plugs
Plugging of Bellini ducts and inner medullary collecting ducts occurs in some patients with idiopathic CaOx stones 11 , in virtually all patients with idiopathic brushite or hydroxyapatite stones 16 and in all stone formers with systemic diseases such as primary hyperparathyroidism 13 ; bowel diseases that involve ileostomy 14 , small bowel resection 15 , obesity bypass procedures 34 ; renal tubular acidosis 35 ; cystinuria 36 and primary hyperoxaluria 37 . The location of Bellini duct plugs means that they are exposed to the tubule fluid on their proximal surface and the urine on their distal surfaces. They can grow upward into the nephron and outwards into the bulk urine (FIG. 3) .
As plugs open onto the urinary space their distal ends are exposed to the supersaturations present in urine. These open ends often have overgrowths 6 , which are sometimes described as 'microliths' . Although the hypothesis is attractive, no proof yet exists that plug overgrowths can increase in size to form clinically relevant stones. Plugging occurs within the renal epithelial compartments, causes obvious local injury, and is an integral part of the complex mineralization of the kidneys of patients who form stones.
Brushite stones.
When brushite is present in stones it is usually the predominant crystal component, although stones can also contain some CaOx or apatite. Patients who form brushite stones show a much wider range of plugging severity than those who form other types of stones. Some papillae can be pristine apart from scattered interstitial apatite plaque (FIG. 4) , whereas others show tubule plugging with crystals, dilated Bellini duct openings, pitting and retraction 17 . Histological changes in plugged tubules include massive dilation, loss of epithelium and peritubular fibrosis. Plugging can be visualized during surgery; dilation of the Bellini duct can be clearly seen, whereas plugged inner medullary collecting ducts are visible through the urothelium as elongate yellow cylinders that reflect crystal casts.
Apatite stones. Stones that are composed predominantly of apatite (>50%; with the remainder being CaOx) are particularly common among women. Much like patients who form brushite stones, patients who form apatite stones also form apatite plugs in their Bellini ducts and inner medullary collecting ducts (FIG. 5) . These plugs are generally smaller and far more numerous than those of patients who form brushite stones. In addition, interstitial calcifications of a kind not seen in other stone formers are also present 16 . These are irregular randomly distributed laminar deposits of interstitial hydroxyapatite and matrix, without microspherules, and with a very high crystal-to-matrix ratio. The importance of these calcifications, which we have termed 'novel interstitial plaque structures' , is not yet known.
As intratubular apatite deposits are so numerous, the tissue of some papillae can be almost completely replaced by crystal plugs, and nephrocalcinosis might be apparent on radiographs. In this respect the papillae are similar in appearance to those found in patients with distal renal tubular acidosis, and careful interpretation of blood and urine testing is necessary to avoid misdiagnosis.
Plug composition. Few plugs have been harvested for study, but their diversity is remarkable (FIG. 3) . A plug isolated from a patient with idiopathic hydroxyapatite stones had a tubule segment composed of hydroxyapatite and an overgrowth of hydroxyapatite and CaOx, whereas a patient with idiopathic brushite stones produced a plug with a tubule segment that contained brushite, hydroxyapatite and CaOx and an overgrowth with a centre of CaOx and an outer region of brushite 16 . A plug from a patient with stones resulting from ileostomy had an hydroxyapatite tubule segment with a pure CaOx overgrowth 6 , and a plug from a patient with primary hyperparathyroidism had an intra tubular portion of hydroxyapatite with an overgrowth of hydroxyapatite 6 . In our analysis of 12 patients with medullary sponge kidney disease we found a single plug, which was composed of a mixture of hydroxyapatite and CaOX in the tubule and overgrowth regions 24 . We also found multiple examples of tiny (500 µm diameter) round microliths made of lamina of hydroxyapatite and CaOx in the dilated and pathological inner medullary collecting ducts of these patients. How these microliths form is unknown.
Cortical changes.
As only ~350 Bellini ducts drain the nephrons of a single kidney 26 , one might expect to find changes in the cortical tissue of patients with substantial plugging in comparison to that of patients in whom plugging is not found. Among patients with idiopathic CaOx stones who did not have plugs, the cortical tissue (FIG. 6) looked similar to that of people without kidney disease 16 . Cortex from patients who formed brushite or hydroxyapatite stones showed scattered regions of scarring and nephron loss 16 . Given this scattered distribution it is unsurprising that such scarring rarely results in a reduction in renal function 16, 17, 38 .
Remaining questions
We know from observation of human kidneys that growth on plaque occurs and is widespread among patients who form calcium stones, whether idiopathic or secondary to systemic disease. Tubule plugs give rise to overgrowths that resemble kidney stones in their composition, but those observed so far are much too small to produce clinical disease. The natural assumption is that these overgrowths increase in size and become clinically relevant stones, but this mechanism remains to be proven. We have not yet found stones of clinically important size attached to plugs, suggesting that overgrowths do not increase in size to form stones in this location. Such growth might occur in the crevasses of the calyces, but no method yet exists to test this hypothesis. The frequencies with which plaque and plugging occur will gradually be defined as larger populations are studied in the future. It is important that such studies clearly document the locations in which stones are forming, so that mechanisms of stone formation can be clarified. Formation in free solution is commonly suggested as a mechanism of kidney stone formation 39 , but proof that this mechanism occurs is lacking. Stones that grow from a plug overgrowth or form in the bulk urine might look the same. The organic stones, cystine and uric acid, might theoretically form in free solution, but no experimental test currently exists to prove this hypothesis in humans. The microliths of patients with medullary sponge kidneys are perhaps the most obvious candidates for formation in free solution 24 . These round, unattached, whorls of hydroxyapatite and CaOx form in the lumens of dilated inner medullary collecting ducts but no proof exists that they grow into clinically significant stones. Finally, the relationship between cortical changes in patients who form brushite or hydroxyapatite stones and clinically important renal disease is unknown. Some evidence supports an increased risk of chronic kidney disease among patients who form stones 40 , which perhaps reflects our findings of cortical scarring in patients with inner medullary duct plugs, but further research is needed.
Formation of crystals
Role of supersaturation Supersaturation is accepted on physical chemistry grounds as the prime source of free energy that drives the nucleation and growth of crystals 41, 42 . The supersaturation of urine with respect to the relevant crystal phases in stones can be estimated using a wellestablished set of measurements 43, 44 and computer programmes that calculate the simultaneous ion equilibria in solution of these stone salts, comparing them to the known thermodynamic solubility constants to derive estimates of supersaturation 43 . At least two supersaturations are always of concern in patients who form calcium stones: CaOx and CaP. Even patients who form the purest idiopathic CaOx stones over plaque and have no tubule plugging require that hydroxyapatite form as the base of these stones 33 . Whether or not specific attempts to regulate both CaP and CaOx supersaturations will lead to improved stone prevention could perhaps be evaluated in future trials. Given the current lack of trial evidence, and little obvious risk, monitoring and controlling both supersaturation values seems prudent as a clinical approach.
With perhaps the exception of minor oxalate secretion in some patients who form idiopathic calcium stones 45 , the main stone crystal components -calcium, phosphate and oxalate -are filtered and reabsorbed so supersaturation of urine cannot exceed that of blood except through water extraction along the nephron. Urine supersaturation is essentially the stored energy produced by water extraction, which can be dissipated by driving phase change 42 . This well-established paradigm emphasizes the remarkable power of simple hydration; by reducing water reabsorption, fluids reverse the primary engine of crystallization.
Inhibition by urine proteins
Modern techniques have identified >1,000 urine proteins 46, 47 , many of which have long been known for their abilities to kinetically retard calcium crystal nucleation, growth and aggregation 48, 49 . Stones contain many such proteins, presumably because their crystals have adsorbed them from urine as they formed 50 . Urine proteins are the main reason why urine can remain stable for days despite supersaturation; simple salt solutions with a similar level of supersaturation are unstable 42 . Essentially, the proteome alters the link between supersaturation and crystallization. In simple solutions, supersaturation and crystallization are tightly related, whereas in urine supersaturation is necessary to achieve crystal formation and prevent crystal dissolution, but a particular level of supersaturation cannot be predicted to result in new crystal formation due to the presence of an unknown number of inhibitors. The idea of comparing the urine supersaturation of healthy individuals and patients who form stones, and identifying a level of supersaturation that will reliably distinguish between the two groups is, therefore, flawed. Patients who form apatite stones can be categorized into two groups on the basis of endoscopy images: those with a | normal appearing compound papillum and those with b | severe changes that resemble those of patients with distal renal acidosis and stones. Panel a | shows a papilla with three separate attached stones (double arrowheads) and no yellow plaque or Bellini duct (BD) plugs, whereas panel b | shows a papilla with numerous regions of yellow plaque (arrows) and a large BD plug (asterisk). Light microscopy images showing c | novel interstitial plaque structures (arrows) -a form of plaque that is unique to patients who form apatite stones -characterized by irregular, large and randomly distributed laminar structures of hydroxyapatite crystal and matrix, and d | numerous plugged inner medullary collecting ducts surrounding an area of extensive interstitial fibrosis in a papilla with severe changes. Micro-CT images of tubular deposits in biopsy samples from e | a normal appearing papilla with no deposits and f | a severely damaged papilla with numerous small deposits. a b c
Crystal interactions
Brushite. In urine, when nucleation is induced in vitro by addition of calcium, the initial phase that forms is usually brushite 51 . Oxalate can bind to calcium atoms on the surface of brushite and begin to form CaOx crystals. As CaOx crystals are less soluble than brushite they are able to cannibalize the brushite provided the solution is supersaturated with respect to CaOx 42, 52 . In the presence of osteo calcin 42 , hydroxyapatite can begin to form on the surface of brushite; a proton is liberated as the monohydrogen phosphate of brushite is taken up into the hydroxyapatite lattice as trivalent negative phosphate ions.
As a result, brushite is usually a transient phase in urine, and one would not generally expect to find brushite in kidney stones. Indeed, large series of stones reported that only ~1% contained brushite 5, 53 . Mechanisms of brushite persistence might involve specific patterns of the urine proteome, but this hypothesis has not yet been investigated. 54 so reduce the amount of calcium that is available to bind with oxalate or phosphate and thereby lower supersaturation with respect to all of the calcium stone crystals 55 . Binding of citrate to brushite crystals widens their growth plates, slows their growth, and inhibits the formation of new brushite as oxalate and apatite use it as a source of ions 42 . Citrate also binds to growth ridges on CaOx crystals and slows their growth 42, 56 . It is important to note that brushite crystal cannibalization has been shown to occur in vitro rather than in whole urine. Likewise the effects of citrate on crystals have only been proven in simple solutions. All crystals follow the same laws of physics, but given the huge urine proteome with its crystal active molecules, the interactions of crystals in urine and with citrate might not be fully predicted by in vitro studies.
Citrate. Citrate ions bind calcium

Idiopathic hypercalciuria
The molarities of calcium, oxalate, phosphate, and citrate, along with urine pH, are the main determinants of supersaturation for CaOx and brushite. These molarities reflect the relationship between solute excretion and urine flow. Hypercalciuria is associated with higher levels of supersaturation at any given urine flow when compared to normal calcium excretion. Idiopathic hypercalciuria is familial 57 , is found in up to 50% of idiopathic calcium stone formers, and is often of considerable magnitude, so it has long occupied the attention of clinicians and scientists 58 . Increases in oxalate excretion and reductions in citrate excretion might well be of equal importance to hypercalciuria in terms of stone formation but are not discussed in this Review.
Definition
Although hypercalciuria can result in renal stones and probably also bone mineral loss and fractures 59 , it is not a disease per se, but rather represents the upper tail of a continuous distribution, similar to height, weight or blood pressure. As urine calcium excretion is a continuously distributed variable it is not ideal or even reasonable to choose a single cut-off point to define 'normal' levels. Rather, similar to blood pressure and body weight, urine calcium excretion should be considered a graded risk factor, and the calcium excretion rate of the individual patient should be considered along with other factors that affect urine supersaturation when making treatment decisions.
Data from epidemiological studies enable correlation of various levels of urine calcium excretion with the relative risk of stone formation 60 . For both sexes, the lower 95% confidence interval (CI) for a relative risk ratio for stone formation of >1 (that is, increased risk) is present at urine calcium levels of about 200 mg daily. This value could, therefore, be considered the lower limit of clinical hypercalciuria and the threshold for consideration of treatment measures aimed at lowering urine calcium excretion. Of course, being a graded risk factor, lowering of urine calcium levels to <200 mg might be appropriate in certain patients, such as those with persistent stone formation.
Mechanisms
Increased gut calcium absorption. In individuals with normal urinary calcium excretion, intestinal calcium absorption rises with dietary intake; on average around 20% of dietary calcium is absorbed in both men and women 61 . By contrast, around 30% of dietary calcium is absorbed in patients with idiopathic hypercalciuria [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . Gastrointestinal calcium absorption is mediated by both epithelial transport and passive paracellular absorption 74 . The increased fraction of dietary calcium that is absorbed in patients with idiopathic hypercalciuria suggests that epithelial transport of calcium is increased in these patients. As the vitamin D hormone system increases epithelial calcium transport, increased calcium absorption in patients with idiopathic hypercalciuria could be the result of increased serum calcitriol levels, increased tissue vitamin D receptor expression or a combination of these factors 4 . Indeed, the serum calcitriol levels of individuals with idiopathic hypercalciuria are generally higher than those of individuals with normal urinary calcium excretion, suggesting that activation of the vitamin D hormone system might be an integral component of idiopathic hypercalciuria 75 . Inbred hypercalciuric rats have normal serum calcitriol levels, but high intestinal and renal vitamin D receptor expression and enhanced intestinal epithelial calcium absorption 76 .
Increased renal calcium loss. Two mechanisms exist by which renal calcium losses might be increased in patients with hypercalciuria: increased filtered load of calcium or reduced tubule calcium reabsorption. Under controlled dietary conditions, the serum concentrations of ultrafilterable calcium in patients with idiopathic hypercalciuria and individuals with normal urinary calcium levels overlap during both fasting and fed periods 77 . Filtered loads of calcium do not differ, and show no tendency to increase with meals in either group. By contrast, the urinary calcium levels of patients with idiopathic hypercalciuria exceeds that of normal fasting individuals, and is increased greatly above normal levels in the fed state 77 . This increase occurs because of a marked fall in overall tubule calcium reabsorption 77 . These data suggest that renal calcium losses are increased in patients with hypercalciuria because of reduced tubule calcium reabsorption rather than increased calcium filtration.
Although the levels of insulin increase and parathyroid hormone decrease with meals, and can differ between individuals with and without hypercalciuria, a decrease in calcium reabsorption in these groups occurs at overlapping levels of these hormones 78 . Likewise, the levels of fractional sodium reabsorption overlap in these two groups 77 . Tubule calcium reabsorption in patients with idiopathic hypercalciuria and in those with normal calcium excretion, therefore, differs independently of insulin levels, parathyroid hormone levels and sodium handling.
The delivery of calcium out of the proximal tubule into more distal nephron segments can be calculated using endogenous lithium clearance as a marker of proximal tubule reabsorption. Using this technique we found that distal calcium delivery was increased in patients with idiopathic hypercalciuria compared to that of individuals with normal calcium excretion 79 .
This finding indicates that the proximal nephron segments contribute to the increase in urine calcium excretion in these patients.
Bone mineral balance
Most patients with idiopathic hypercalciuria seem to have increased intestinal calcium absorption coupled with decreased renal calcium reclamation. However, urinary calcium excretion often exceeds gut calcium absorption in balance studies, and when dietary calcium intake is very low, patients with idiopathic hypercalciuria can excrete more calcium than they ingest 80 . These data suggest that idiopathic hypercalciuria will cause bone disease when patients are challenged with a low calcium diet for stone prevention. Consistent with this hypothesis, many studies have shown reduced bone mineral density and an increased incidence of fractures among patients with idiopathic hypercalciuria 59 . This finding is one reason why low calcium diets are not advisable for the treatment of stone formers with idiopathic hypercalciuria. As patients with idiopathic hypercalciuria seem to have a generalized alteration of both gut and renal calcium handling, and are at risk of bone loss, attempting to separate patients into those with primarily absorptive or renal hypercalciuria is not clinically useful.
Patient management
Management of supersaturation
The urine supersaturation of a patient who is actively forming new stones is clearly too high with respect to the crystals in the stones that are being formed. Current stone treatments aim to decrease urinary supersaturation relative to the stone mineral by a substantial margin, perhaps by half. Lowering urine supersaturation often requires multiple interventions, which might include increased fluid intake, dietary counselling, and medications. Interventions should target the factors that are most likely to be raising the supersaturation in the individual patient, which can be determined using 24 h urine samples collected before treatment. Depending on stone (and supersaturation) type, these could include inadequate urine volume, elevated urine calcium, oxalate or uric acid or low urine citrate. A general approach to stone prevention is outlined in BOX 1. Although no trials have specifically investigated whether management of supersaturation for prevention of stone formation is more effective than routine drug therapy without such management 81 , we believe that management of supersaturation is justified and clinical trials of such an approach are reasonable. Patients should always be followed up with 24 h urine measurements 4-6 weeks after treatment is initiated, to assess the success of treatment at lowering supersaturation. If supersaturation persists, treatment can be adjusted according to the persistent risk factors.
Fluid intake
In normal individuals and hypercalciuric calcium stone formers fed identical diets, levels of urine supersaturation vary with urine flow rate and food intake throughout the day (FIG. 7) . During fasting, supersaturations of CaOx and CaP increase steeply as urine flow rate falls below 100 ml/h 82 . The relationship between supersaturation and urine flow is less regular for CaP than for CaOx because urine pH strongly influences CaP supersaturation 5 but not CaOx supersaturation. However fluid intake markedly decreases supersaturation for both stone salts. A urine flow of 100 ml/h during fasting and overnight, and 125 ml/h when fed would be predicted to minimize urine supersaturation. Given an estimate of 0.9 l per day (40 ml/h) insensible water losses 83 among patients who are not exposed to an extreme of climate, fluid intakes of 140 ml/h during fasting and overnight and 165 ml/h when fed would be expected to achieve this urine flow. Lifestyle habits, climate, working conditions, and the use of therapies that lower urine calcium or oxalate excretion might alter these requirements. Our calculations suggest an ideal fluid intake of about 3.5 l per day to reduce the risk of stone formation; however, an intake of this volume might not be practical. As patients might not accurately know their urine volumes, measurement of these volumes during treatment is essential.
Validation of the importance of fluids was provided by data from a randomized trial of water intake in 200 idiopathic patients who had formed a single calcium stone 84 . After 5 years, 12% of patients who increased their urine volume from 1,068 ml at baseline to 2,061 ml during treatment, had a recurrent kidney stone, compared to 27% of those in the control group, whose baseline urine volume of 1,008 ml did not change during the study (P = 0.008). Supersaturations for both calcium oxalate and calcium phosphate decreased significantly in the treatment group.
Low sodium diet
Urine calcium excretion is linearly related to urine sodium excretion, in both normal individuals and stone formers, and lowering sodium intake can lower urine calcium levels. A number of controlled experiments have documented the effects of changes in dietary sodium intake on urinary calcium excretion in healthy individuals [85] [86] [87] [88] [89] [90] [91] [92] [93] and in patients with idiopathic hypercalciuria 88, [92] [93] [94] [95] [96] [97] [98] . Moreover observational studies have shown changes in urine calcium levels in these groups when dietary sodium levels have changed spontaneously 95, [99] [100] [101] . A study of men with idiopathic hypercalciuria and calcium stones compared the effects of a low calcium, low oxalate diet to those of a diet with 1,200 mg calcium, reduced sodium, oxalate and protein 102 . In this study, 23 of 51 patients on the low calcium diet and 12 of 52 patients on the reduced sodium and protein diet formed a new stone over 5 years (P <0.01). The relative contributions of the lowered sodium and protein intakes on stone formation cannot be determined. However, given its remarkable ability to lower urine calcium, a trial of low sodium diet alone versus thiazide might be justified.
No data are available on the effect of sodium on bone balance in patients with idiopathic hypercalciuria, but the findings of a study of dietary sodium and calcium intakes in menopausal women suggest that a reduced sodium diet might benefit bone balance in the setting of idiopathic hypercalciuria 89 . As expected, calcium absorption was higher in women who received high calcium diets than in those on low calcium diets and calcium balance was negative in the low calcium diet groups. In the low sodium, high calcium diet phase, bone balance became positive because calcium absorption was the same as for the high sodium, high calcium diet, but faecal and urine calcium losses were reduced with reduced dietary sodium.
In patients who are hypercalciuric, dietary calcium should be ample (≥1,200 mg) and dietary sodium should ideally be restricted to <1.5 g (65 mmol) per day as recommended for the US adult population by the Centers for Disease Control and Prevention
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. This low sodium diet has the potential to reduce urine calcium levels and possibly maintain or even increase bone mineral stores. It is preferable to obtain calcium from foods rather than supplements, but if supplements are used they should be taken with meals.
Thiazide and thiazide-like diuretics
Thiazide diuretics lower urinary calcium excretion 104 and have been used to prevent the formation of calcium stones 105 . The effectiveness of this therapy is presumed to arise from the hypocalciuric action of thiazide, although this hypothesis has not been rigorously tested.
Among a welter of shorter trials of thiazide diuretics for stone prevention, three stand out for being randomized controlled trials with a treatment period of 3 years. First, in 1984, Laerum et al. showed that treatment with hydrochlorothiazide (25 mg twice daily) reduced stone recurrence in patients with urolithiasis; 10 of 25 patients in the placebo group formed a new stone compared with only four of 23 patients in the hydroclorothiazide group (P <0.01) 106 • Daily fluid intake should be high (>3 l on average) to achieve at least 2 l of urine daily; fluid intakes ≥3.5 l daily to achieve urine volumes of ≥2.5 l daily are advisable with adjustments for higher fluid needs depending on work, climate, and lifestyle. Accurate measurement of urine volume during treatment is essential.
• In patients who are hypercalciuric, dietary calcium levels should be at least 1,200 mg daily (calcium should be obtained preferably from food rather than supplements) and dietary sodium levels should be restricted to <1.5 g daily.
• We suggest using thiazide diuretics when high urine volume and reduced sodium intake fail to reduce supersaturations to half of their original values, when this end point has been reached but new stones form, and in patients who are unable or unwilling to alter their fluid and sodium intake sufficiently to reduce stone risk.
• Urine citrate levels should be increased to >400 mg daily using potassium citrate or other oral potassium-based alkali.
• In patients with urinary citrate ≥400 mg daily or with calcium phosphate stones, the use of alkali supplements has not been specifically tested and theoretical considerations suggest a possible adverse effect in the latter instance. 
Overnight
Idiopathic hypercalciuria Normal
Urine flow (ml/h) Urine flow (ml/h) Urine flow (ml/h) versus 4 of 28 patients in the treatment group formed a new stone (P <0.01) 107 . Finally in 1993, Borghi et al. showed that treatment with indapamide (2 mg daily) reduced stone recurrence in patients with calcium nephrolithiasis and hypercalciuria; nine of 21 patients in the placebo group and only six of 43 patients in the treatment group formed a new stone during the treatment period (P <0.01) 108 Although all three studies were limited by incomplete follow up of lost participants, and another randomized trial might be justified, these data suggest that thiazide is effective for stone prevention.
In four men, we performed a complete analysis of tubule reabsorption before and after 6 months of treatment with chlorthalidone 25 mg daily 109 . Thiazide reduced urine calcium excretion, fractional calcium excretion, and fractional lithium excretion, indicating that its effect involves reduced distal delivery of calcium out of the proximal tubule. These results suggest that thiazide might not only reduce stone formation, but also formation of interstitial plaque, but this hypothesis remains to be tested experimentally.
Data from balance experiments has demonstrated that thiazide therapy can improve bone mineral balance in idiopathic hypercalciuric stone formers. We found that chlorthalidone therapy (25 mg daily for 6 months) lowered net intestinal calcium absorption to a lesser extent than urine calcium excretion, so net bone balance increased 110 . Additional studies have shown increases in bone mineral density 111 and a reduction in fracture rates 112 with thiazide agents. We tend to treat patients with thiazide diuretics when high urine volume and reduced sodium intake have failed to bring urine supersaturations to half of their original values, when this end point has been reached but new stones occur, and in patients who cannot or will not alter their fluid and sodium intake sufficiently to reduce stone risk.
Potassium citrate
Given its multiple roles in calcium binding and as an inhibitor of the formation of all three types of common stone crystal species, citrate is theoretically an important defence against stone formation. Consistent with this hypothesis, reduced levels of citrate correlated with new onset of stones in long-term observational studies of men and women 60 . For both sexes, the upper 95% CI for the relative risk ratio of becoming a stone former is <1 when citrate excretion is >400 mg daily; lower levels of citrate excretion confer progressively increased risk of stone formation 60 . Treatment with potassium citrate or another oral potassium-based alkali should, therefore, be used to increase urine citrate levels to >400 mg daily and reduce the risk of stone formation in patients with idiopathic calcium stones.
Oral citrate intake increases urine citrate levels by imposing an alkali load as the citrate is metabolized as citric acid 113, 114 . Perhaps as a mechanism of removing alkali without raising urine pH, the kidneys reduce renal citrate reabsorption via effects on the main citrate transporter in the proximal tubule 115 . Urine bicarbonate excretion often increases in response to oral citrate intake, resulting in increases in urine pH and CaP supersaturation 113 . Potassium citrate -or potassium alkali of any kind -lowers urine calcium excretion in patients who form stones 116 or in patients with bone diseases 117 . This effect probably occurs because the alkali neutralizes chronic dietary acid load 117 . As metabolic acidosis decreases proximal tubule sodium reabsorption 118, 119 via a number of mechanisms 120, 121 , reversing the chronic acid load from diet will likely increase sodium reabsorption, which will help to conserve filtered calcium and decrease calcium excretion. Distal effects of diet acid load and its reversal have not yet been studied in humans or proven in experimental models.
Calcium stones. Potassium citrate treatment has been shown to reduce the formation of new calcium stones, but no trial has specifically targeted patients who form CaP stones; the majority of participants in the published studies made CaOx stones. In the first of two double-blind randomized controlled trials, 16 of 20 patients in the placebo group who completed 3 years of follow-up formed a new calcium stone compared to five of 18 patients who received potassium citrate 122 . In the second trial 123 , 16 of 25 patients in the placebo group and two of 16 patients in the treatment group formed a new calcium stone after 3 years of follow up. In both of these trials the reduction in stone formation with therapy was statistically significant. A third randomized controlled trial that was not double blinded showed no significant difference in stone formation between the study groups; six of 22 patients in the placebo group and five of 16 patients in the treatment group produced new stones over 3 years 124 . The difference from the other two trials is clearly the unusually low rate of recurrence in the placebo group. In two randomized controlled trials that followed patients after shock wave lithotripsy, those treated with potassium citrate had lower rates of retained fragment growth and new stone formation than untreated controls after 12 months of follow up 125, 126 .
Brushite and apatite stones. The effect of potassium citrate on formation of brushite and apatite stones is unclear. On the one hand, inhibition of brushite and hydroxyapatite formation, a reduction in urine calcium excretion, and a reduction in free calcium ions in urine should reduce CaP supersaturation and formation of CaP stones. On the other hand, higher urine pH directly increases supersaturation with respect to brushite 5, 116 and fosters hydroxyapatite formation by providing increased receptors to take up the protons that are liberated as brushite is converted to hydroxyapatite 127 . The effect of potassium citrate on the formation of brushite or hydroxyapatite stones has not yet been evaluated in a clinical trial. In the meantime, physicians who use citrate might mitigate the risk of stone formation by closely monitoring the increases in urine pH, CaP supersaturation and citrate excretion after starting treatment, and adjusting treatment accordingly. If stone recurrence persists, use of citrate should be re-evaluated.
Conclusions
Many patients who form idiopathic calcium stones are hypercalciuric. Supersaturations of CaP and CaOx in the urine and local to the papillary interstitium foster the formation of interstitial apatite plaque, overgrowth of amorphous apatite on exposed plaque, and the formation of the main CaOx body of attached stones. Citrate and some urine proteins kinetically slow the process of stone formation, but plaque overgrowth might eventually create stones despite these inhibitors. Supersaturations also create tubule plugs but exactly how this process occurs and whether the tiny overgrowths found on plugs become clinically significant stones is unknown. Idiopathic hypercalciuria is a renal disorder that results from reduced tubule calcium reabsorption. Further research is needed to clarify whether activation of the vitamin D hormone system with abnormally high intestinal calcium absorption occurs secondary to calcium losses in patients with hypercalciuria or is a primary component of the renal disorder. Importantly, low calcium diets are inappropriate and can cause harmful losses of bone mineral in these patients. Despite the remaining questions, the available data suggest that high fluid intake, a low sodium diet and treatment with potassium citrate and thiazide diuretics are practical and effective approaches for stone prevention in idiopathic patients.
